Q2 2025 EPS Estimates for CRISPR Therapeutics AG Reduced by Analyst (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, July 30th. Zacks Research analyst R. Department now expects that the company will post earnings of ($1.60) per share for the quarter, down from their prior estimate of ($1.58). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.52) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.48) EPS, FY2025 earnings at ($6.14) EPS, Q1 2026 earnings at ($1.47) EPS, Q2 2026 earnings at ($1.49) EPS and FY2026 earnings at ($5.30) EPS.

Other research analysts have also issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $88.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, June 27th. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Oppenheimer cut their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Finally, Robert W. Baird lifted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.71.

CRISPR Therapeutics Trading Up 1.6 %

Shares of NASDAQ:CRSP opened at $57.29 on Thursday. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10. The company has a market capitalization of $4.87 billion, a price-to-earnings ratio of -21.06 and a beta of 1.70. The firm’s 50-day moving average is $57.30 and its 200 day moving average is $63.40.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same period last year, the firm earned ($0.67) earnings per share. The firm’s revenue for the quarter was down 99.5% compared to the same quarter last year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Van ECK Associates Corp increased its stake in CRISPR Therapeutics by 10.9% during the 2nd quarter. Van ECK Associates Corp now owns 79,774 shares of the company’s stock valued at $4,309,000 after purchasing an additional 7,830 shares in the last quarter. Banque Cantonale Vaudoise lifted its position in CRISPR Therapeutics by 4.7% during the 2nd quarter. Banque Cantonale Vaudoise now owns 17,376 shares of the company’s stock worth $939,000 after acquiring an additional 782 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of CRISPR Therapeutics by 14.0% in the second quarter. Commonwealth Equity Services LLC now owns 61,559 shares of the company’s stock worth $3,325,000 after purchasing an additional 7,560 shares during the last quarter. EMC Capital Management boosted its position in CRISPR Therapeutics by 830.0% in the second quarter. EMC Capital Management now owns 9,300 shares of the company’s stock valued at $496,000 after buying an additional 8,300 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in CRISPR Therapeutics in the 2nd quarter worth approximately $470,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.